Detail for Tacrolimus
Basic Information
DrugID 110
DrugName Tacrolimus
DrugDetail Tacrolimus (also FK-506 or fujimycin, trade names Prograf, Advagraf, Protopic) is an immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It is also used in a topical preparation in the treatment of atopic dermatitis (eczema), severe refractory uveitis after bone marrow transplants, exacerbations of minimal change disease, and the skin condition vitiligo. It is a 23-membered macrolide lactone discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. It reduces interleukin-2 (IL-2) production by T-cells.

http://en.wikipedia.org/wiki/Tacrolimus

Indication For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.

http://www.drugbank.ca/drugs/DB00864

Structure
Interaction
Drug Name PMIDLink Reference
Itraconazole Dannaoui E., Schwarz P., Lortholary O. (2009) In Vitro Interactions between Antifungals and Immunosuppressive Drugs against Zygomycetes. Antimicrobial Agents and Chemotherapy 53:3549-3551. DOI: 10.1128/aac.00184-09
ravuconazole Dannaoui E., Schwarz P., Lortholary O. (2009) In Vitro Interactions between Antifungals and Immunosuppressive Drugs against Zygomycetes. Antimicrobial Agents and Chemotherapy 53:3549-3551. DOI: 10.1128/aac.00184-09
Target
PathWay